Alginate Polymers for Drug Delivery by St. Martin, Anne Louise & Brunetti, Michael C.
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2006
Alginate Polymers for Drug Delivery
Anne Louise St. Martin
Worcester Polytechnic Institute
Michael C. Brunetti
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
St. Martin, A. L., & Brunetti, M. C. (2006). Alginate Polymers for Drug Delivery. Retrieved from https://digitalcommons.wpi.edu/mqp-
all/2364
Project Number: MQP TAC-FR08 
Alginate Polymers for Drug Delivery 
 
 
 
A Major Qualifying Project Report 
 
submitted to the Faculty of  
 
WORCESTER POLYTECHNIC INSTITUTE 
 
in fulfillment of the requirements for the 
 
Degree of Bachelor of Science 
 
 
by 
 
 
_______________________________________ 
Michael Brunetti 
 
 
_______________________________________ 
Anne St. Martin 
 
Date: April 27, 2006 
 
Approved: 
 
 
 
______________________________________ 
Professor Terri A. Camesano, Advisor 
 
 
______________________________________ 
Professor W. Grant McGimpsey, Co-Advisor 
 i 
Acknowledgements 
 
We would like to express our gratitude to everyone who advised and assisted with our research 
throughout our time at ENSIC. We sincerely appreciate their time and efforts. 
 
Professor Terri Camesano, WPI, Project Advisor 
Professor Grant McGimpsey, WPI, Project Advisor 
Monsieur Alain Durand, LCPM, ENSIC, Site Advisor 
Madame Michèle Léonard, LCPM, ENSIC, Site Advisor 
Madame Marie-Christine Grassiot, LCPM, ENSIC, Professor 
Monsieur Frédéric Vallée, LCPM, ENSIC, Etudiant Doctorate 
 ii 
Abstract  
The goal of this project was to investigate the properties of alginate stabilized emulsions and 
their potential role for drug delivery.  The polymer acts as a barrier between phases in oil-in-
water emulsions to increase stability.  An emulsion consisting of 10% oil by volume with 1.4 
mg/mL alginate as a surfactant was found to be most stable.  Kinetic release experiments showed 
that using the emulsion provided a controlled release of the model drug when compared to no 
emulsion at all. 
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Introduction 
In the field of medicinal chemistry a substantial challenge lies in developing drugs that 
can be administered by the traditional oral methods.  During drug research and development, 
molecules that are not suitable for these classic delivery systems are typically discarded due to 
the high costs of developing corresponding delivery systems.  A drug delivery system capable of 
releasing drugs with poor oral bioavailability would greatly increase the development rate of 
novel medications. 
Recent investigations in the area of controlled drug delivery have the potential to solve 
the problem of poor bioavailability through polymer-drug combinations that are able to release 
the active drug in a pre-designed manor.  This release can be either cyclic or over a long period 
of time, and it may be triggered by external environmental events.  In either case, the exact 
mechanism is studied and developed to ensure the successful delivery of drug therapies while 
preventing the problems of both over and under dosing.  In addition, controlled drug delivery 
allows for the maintenance of a desired range of drug levels, requires fewer administrations, and 
optimizes the therapeutic use of the drug.  Specifically these delivery systems are ideal for the 
slow release of water soluble drugs, the fast release of low-solubility drugs, drug delivery to 
specific sites, drug delivery using nanoparticulate systems, delivery of two or more agents with 
the same formulation, and systems based on carriers that can dissolve or degrade and be readily 
eliminated.  An ideal system should be mechanically strong, inert, comfortable to administer, 
biocompatible, safe from accidental release, easy to fabricate and sterilize, and capable of 
loading high levels of the desired drug (Brannon-Peppas, 1997).  
The ultimate goal within controlled drug delivery investigations is to yield an optimally 
high blood level of the drug over an extended period of time.  With traditional oral and injection 
methods, the blood drug level follows a pattern as illustrated in Figure 1(a) as the specific level 
rises after each administration and decreases quickly until the next administration (Brannon-
Peppas, 1997). 
The aim of drug administration is to maintain a steady blood level of the specific drug 
over an extended time period that does not go below a minimum concentration of effectiveness, 
or above a maximum level of possible toxicity.  With controlled drug delivery, the drug level 
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over time represents a steadier curve, as represented in Figure 1 (b), reaching above the 
minimum concentration level for an extended period of time while not exceeding the maximum.  
Alginate is a naturally occurring biopolymer that has many possible applications in the 
area of drug delivery.  Extracted from brown algae, alginate polymers consist of linear, 
unbranched polysaccharides with acid residues of 1,4’-linked-β-D-mannuronic acid and α-L-
gluronic acid residues.  The residues are arranged in blocks along the chain and vary in sequence 
and composition.  Used for many years in food and beverage industries, alginate polymers are 
currently under investigation for drug delivery applications due to their nonimmunogenicity as 
naturally derived biopolymers (Gombotz and Wee, 1998).  In addition, alginate matrices have the 
  
Figure 1.  Blood Circulation Drug Level With Oral Drug Delivery (a) and Controlled 
Drug Delivery (b) 
 3 
ability to encapsulate protein (Tanaka, Matsumara et al.), 1984, and DNA (Smith, 1994) while 
maintaining biological activities and have illustrated very strong bioadhesive abilities making 
alginate a promising candidate for site-specific mucosal delivery (Mestecky, 1987).   
An area of controlled drug delivery currently under investigation at ENSIC is the use of 
polymer surfactants in oil-water emulsions.  While research has been focused on the use of 
dextran polymer as surfactant in these emulsions, the researchers are also interested in the 
possibility of using modified alginate polymer.  Alginate-protein matrices are currently under 
investigation by ENSIC researchers (Léonard, Rastello de Boissen et al., 2004), and the idea of 
using the alginate polymer as a surfactant in the emulsion drug delivery investigations was 
identified as a promising research avenue. 
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Background 
Research is currently being conducted at ENSIC on various methods for controlled drug 
delivery.  Namely, polymer stabilized emulsions are currently under investigation using 
hydrophobically modified dextran polymers, and the results have merited further investigation.  
In addition, alginate polymer-protein matrices have also been under investigation for controlled 
drug release, and have also proven to be very promising.  Our research was designed to 
investigate the possible use of hydrophobically modified alginate polymers as stabilizers in 
oil/water emulsions, and then to test the drug encapsulation and release kinetics of these 
emulsions. 
This section outlines the theory behind polymer-stabilized emulsions for drug release, as 
well as the use of alginate polymer in various areas of controlled drug delivery investigation. 
Alginate Chemistry 
As a naturally occurring biopolymer, alginate has been used successfully in the food and 
beverage industry as a gelling agent and colloidal stabilizer, and holds strong potential in the area 
of drug delivery.  Extracted from brown algae, alginate polymers consist of linear, unbranched 
polysaccharides with acid residues of 1,4’-linked-β-D-mannuronic acid and α-L-gluronic acid 
residues.  The residues are arranged in blocks along the chain and vary in sequence and 
composition.  There are numerous physical characteristics possessed by alginate that enable it to 
form matrices to encapsulate and deliver various proteins and cells in vivo.  Specifically, alginate 
matrices contain aqueous internal environments ideal for the encapsulation of proteins and small 
molecules.  These encapsulations form at room temperature, independent of organic solvents, 
and they have a high rate of macromolecular diffusion due to their porous gel state that may be 
controlled through specific coating procedures.  In addition, alginate matrices are very 
biodegradable and can be broken down under normal physiological conditions (Gombotz and 
Wee, 1998).  
Sources of Alginate 
Alginate is extracted for commercial purposes from various species of kelp, or brown 
algae including Laminaria hyperborean, Ascophyllum nodosum, and Macrocysis pyrifera 
(Smidsrod and Skjak-Braek, 1990).  Within the kelp species, alginate is found in the intracellular 
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matrix where it constitutes up to 40% of the dry weight.  The alginate forms mixed slats with 
various cations naturally found in sea water including Mg2+, Ca2+, Sr2+, Ba2+, and Na+, and the 
native species is usually found as an insoluble Ca2+ cross-linked gel (Sutherland, 1991).   
When alginate is harvested, the algae is mechanically collected and dried, then the 
material is milled and treated with dilute acid to remove and dissociate neutral 
homopolysaccharides and exchange the alkaline earth cations with H+ before the alginate in 
extracted.  With the addition of sodium carbonate below pH 10, the alginate is then converted to 
the soluble sodium salt from the insoluble protonated form and can be further purified and sold 
in salt or acid form (Sutherland, 1991). 
Due to the natural extraction process used to obtain alginate, there are many impurities 
that may potentially contaminate the product.  These impurities include heavy metals, endotoxin, 
proteins, other carbohydrates, and polyphenals contained in the kelp (Smidsrod and Skjak-Braek, 
1973).  When harvested alginate is used in food and drug industries small traces of theses 
impurities are acceptable, but when it comes to medicinal applications they must be removed.  
New methods of harvesting and purification have been developed to address the problem of 
contamination, and now pharmaceutical grade alginate is available from numerous chemical 
manufactures.  
Chemical Structure 
Alginate polymers are linear unbranched polysaccharides consisting of 1,4’-linked-β-D-
mannuronic acid and α-L-gluronic acid residues as represented in Figure 2.  The pattern held by 
these residues varies greatly and are arranged in a block pattern along the length of the chain 
backbone. 
The homopolymeric regions of β-D-mannuronic acid blocks and α-L-gluronic acid 
blocks are interdispersed with alternating regions of 1,4’-linked-β-D-mannuronic-acid-α-L-
gluronic acid blocks as seen in Figure 2 (Haug, Larsen et al., 1967).  The distribution of 
monomers along the polymer chain is random and therefore alginates do not have a repeating 
unit.  However, the molecular variability of the polymer is reflective of the organism from which 
the polymer is extracted.  For instance, alginates isolated from L. hyperboea kelp have a high 
number of α-L-gluronic acid residues, while alginates isolated from A. nodosum and L. japonica 
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have a low content of α-L-gluronic acid blocks.  The overall composition and resulting 
molecular weight of the alginates determines the physical properties of the polymer.  Namely, 
the viscosity depends greatly on the molecular weight of the material. 
Gel Formation 
The preparation of alginate beads containing an assortment of substances can be achieved 
through various means.  These approaches cover large bead preparation, microbead preparation, 
matrix block preparation, and in situ gelling systems.  In general, alginate beads are formed when 
a solution of sodium alginate and the desired substance is extruded as droplets into a divalent 
solution to encourage cross-linking of the polymers.  Such cross-linking solutions may include 
cations such as Ca2+, Sr2+, or Ba2+, while monovalent cations and Mg2+ do not induce gelation, 
and Ba2+ and Sr2+ ions produce very strong alginate gels (Clark and Ross-Murphy, 1987).  
Numerous other cations including Pb2+, Cu2+, Cd2+, Co2+, Ni2+, Zn2+, and Mn2+ will induce 
gelation, but due to their toxicity they are rarely used.  In the gelation process, the polymer 
chains are cross-linked by the exchange of sodium ions from gluronic acids with divalent 
cations, forming what is referred to as the “egg-box” as represented in Figure 3 (Rees and Welsh, 
                                                 
1
 http://www.kjemi.uio.no/Polymerkjemi/Research/alginate.jpg 
 
Figure 2.  The chemical structure of alginate with β-D-mannuronic (M) 
acid blocks and α-L-gluronic (G) acid blocks 1 
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1981).  In the case of Ca2+ ions, the cation binds to the α-L-gluronic acid residues forming 
dimerizing junctions with other chains, producing soluble gellous networks (Rees and Welsh, 
1997).  Unfortunately, in biological systems the Ca 2+ ion is lost to phosphate, resulting in the 
breaking of all preformed cross-links.  However, this problem may be avoided through the 
modification of alginate with long alkyl chains, as the hydrophobic interactions of the divalent 
cation are not required to form the gellous networks, as the hydrophobic interactions in the alkyl 
chains are sufficient to bond the polymer.  Moreover, this interaction is strengthened by salt 
concentrations, and the greater the salt concentration, the greater the stability of the modified 
alginate networks. 
Large Bead Preparation 
Beads of diameter greater than 1.0 mm are usually prepared by transferring drop wise a 
solution of sodium alginate and solubilized protein into an agitated divalent cross-linking 
solution (Elquin, 1995).  The size of the needle and the viscosity of the alginate solution will 
determine the diameter of bead formed, with the larger needle and more viscous solutions 
producing larger diameter beads.  As well, the viscosity of the alginate often also influences the 
shape of the bead produced.  As the concentration of the sodium alginate is increased, the beads 
produced become more spherical (Badwan, Abumalooh et al., 1985).   
Matrix Gels, Fibers, and In Situ Gelling Systems 
Alginate gels of different forms than spherical beads have also been prepared with 
substance loading through either inhibition or incorporation of the protein into the alginate 
                                                 
2
 (Gombotz and Wee, 1998) 
     
Figure 3.  Egg-Box association of poly-L-guluronate sequences of alginate and conversion of random coils to 
ribbon structures when cross-linked with calcium ions2         
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solution before cross-linking (Liu, Ng et al., 1997).  To form a block matrix the alginate solution 
with substance is poured into a container and leveled before being placed in the cross-linking 
solution for gelation.  This process may take several hours, and afterwards the gels may be cut 
into the desired shapes.  With the inhibition method, the block gel is immersed in a solution of 
the protein of interest, however this method requires a greater amount of protein and a greater 
length of time to form (Bhakoo, Woerly et al., 1991). 
Microbead Preparation 
When the desired beads are less than 0.2mm in diameter, there are three main methods 
used for microbead preparation; atomization, coacervation, and emulsification, the method used 
in our drug release experiments.   
In general atomization preparation, microbeads are prepared from well mixed solutions of 
alginate and substance which are loaded into a syringe mounted on a pump, and pressured 
through an atomization device with a small diameter orifice at the tip.  The orifice usually spans 
~1mm in diameter, and although smaller diameter tips may be used, they run the risk of 
becoming clogged by the viscous alginate solution.  In the case of microbead preparation, the 
size of the beads can be controlled by either the flow-rate of the syringe pump, the pressure of 
the infusing nitrogen gas, or the distance between the orifice and the surface of the cross-linking 
solution.  When cross-linked with the divalent solution, the fine droplets of alginate/substance 
solution will form microbeads, which may then be coated (Kwok, Groves et al., 1991).  
Another method of microbead preparation is the complex coacervation of oppositely 
charges polyelectrolytes.  With this method, specific conditions of polyion concentration, pH and 
ionic strength, the mixture will separate into a dense coacertive phase containing the microbeads 
and a dilute equilibrium phase (Bugenberg de Jon, 1949).  For example, complex coacervation 
between alginic acid and chitosan was achieved by spraying the sodium alginate solution into the 
chitosan solution, producing strong microbeads that remained stable over a large range of pH.  
For the best yield with coacervative bead preparation conditions should be set to a pH of 3.9, an 
ionic strength of 1 mM, and a 0.15% w/v total polyion concentration (Daly and Knorr, 1988). 
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Alginate as Surfactant in Emulsion Bead Formation 
Another method of microbead preparation involves the use of alginate polymer as a 
surfactant stabilizer in oil-water emulsions.  Alginate surfactants serve to lower the interfacial 
energy between the phases, thereby increasing the stability and lifetime of the emulsion. 
Emulsion Formation 
Emulsions are formed when two immiscible substances are combined, with one substance 
being dispersed in the continuous phase substance as can be observed in Figure 4.  Emulsions 
fall into a greater class of two-phase systems known as colloids, with the special characteristic 
that both the dispersed and continuous phases are liquid.  Depending on the volume fraction of 
the phases, both water-in-oil and oil-in-water emulsions can be formed.  There is a rule which 
governs the emulsion formation, known as the Bancroft Rule: emulsifiers and emulsifying 
particles tend to promote dispersion of the phase in which they do not dissolve well; for example, 
proteins dissolve better in water than in oil and therefore tend to form oil-in-water emulsions, 
promoting the dispersion of oil droplets throughout a continuous phase of water 
(www.wikipedia.org).  Emulsions often have a cloudy appearance due to the scattering of light 
as it passes through the many interfaces contained within the emulsion. 
Emulsions can be prepared through various methods of agitation, as the two phases are 
immiscible and droplets will not form spontaneously.  Methods for emulsion preparation include 
sonication, which can produce droplets of 100 to 400nm.  When investigating emulsions for drug 
release experiments, the desired drug is dissolved into the oil, and then combined with the 
A                B  
C                D  
Figure 4.  (A) Two immiscible liquids not emulsified (B) An emulsion of phase B dispersed in Phase A (C) The 
unstable emulsion (D) The purple surfactant as an emulsion stabilizer 
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alginate and aqueous phase and agitated to form polymer stabilized oil-in-water emulsions 
containing the desired drug. 
Polymeric Surfactants 
When emulsions are formed, they are thermodynamically unstable, the result of the 
degree of mechanical energy needed to form the emulsion droplets in compensation for the 
increasing of interface area between the two (Sadtler, Imbert et al. 2002).  Polymeric surfactants 
on these emulsions have been used to solve this problem of instability by lowering the surface 
tension between the liquid phases.  Polymeric surfactants are widely used as emulsions 
stabilizers in biotechnology and drug delivery processes, and are commonly referred to as 
emulsifiers, detergents, or dispersants. 
As amphiphilic molecules, polymers have two main regions, a soluble lyophilic region, 
and an insoluble lyophobic region.  The polymer chain coils itself around the oil droplets, with 
the hydrophobic regions anchoring into the oil and the hydrophilic regions branch out to the 
aqueous phase.  The anchoring of hydrophilic branches provides stability against washing, while 
increasing steric stability and overall emulsion stability (Tadros, Vandamme et al., 2004).  As 
well, these surfactants provide steric repulsion between oil droplets, and help protect against 
aggregation.  Polymer surfactants are highly researched because of their strong ability to lower 
surface tension and thicken the aqueous phase of emulsions.  Moreover, their biocompatibility 
makes them prime candidates for biological applications.  
Dry Emulsions 
Once emulsions are formed, they can be dried to increase stability for drug delivery and 
ensure a longer shelf life.  Liquid state emulsions are physically unstable, and the stability of the 
emulsion beads is greatly increased upon removal of the solvent (Dollo, Corre et al., 2004).  This 
can be accomplished through freeze-drying, where the aqueous phase is frozen and then removed 
with a vacuum through sublimation.  Freeze-drying, also known as lyophilization, further 
stabilizes the emulsion because it is a very unobtrusive method and avoids higher temperatures 
usually involved with solvent removal.  Once the emulsions are dried, they can them be 
compressed into pill form for easier administration, or they can be stored in solid state for an 
extended period of time.  Dried emulsions can be easily reconstituted by adding a specific 
amount of the continuous phase as was previously removed, and using light vortex and 
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sonication techniques.  However, it is difficult to reconstitute emulsions of the same size before 
freeze drying as droplets usually aggregate during the drying process and often form larger 
particles (Christensen, Pedersen et al., 2001).  
Physical Properties of Alginate Beads 
The properties of cation cross-linked alginate beads are dependent on the structure, 
composition, and molecular size of the polymer beads (Martinsen, Skjak-Braek et al., 1991).  
The polymer solution flexibility is dependent on the concentration of β-D-mannuronic acid and 
α-L-gluronic acid blocks in the order MG>MM>GG (Haug, Larsen et al., 1967).  Beads with 
lowest shrinkage, greater porosity, mechanical strength, and highest stability towards 
monovalent cations consist mainly of α-L-gluronic acid, with an average content of at least 70% 
and an average α-L-gluronic acid block length of 15.  Referred to as High G alginates, when 
these polymers have a molecular weight exceeding 2.4×105, the strength of the gel will be 
independent of the molecular weight (Martinsen, Skjak-Braek et al., 1991).  While gels made 
with low α-L-gluronic acid content will be more elastic, those produced with a high α-L-
gluronic acid content will be more brittle (Chapman and Chapman 1980).  In addition, alginate 
will form stable gels within the temperature range of 0-100°C, however the higher the 
temperature during formation, the less rigid the gels produced will be (Gacesa, 1988). 
Chemical Reactivity 
Due to the high water content of alginate beads, which is around 95%, the 
microenvironment of alginate is usually inert to protein drugs and cells.  However, a positively 
charged protein can compete with calcium ions for available carboxylic acid sites on the alginate 
chains (Segi, Yotsuyangi et al., 1989).  It has been observed with the case of transforming 
growth factor-beta (TGF-β1) that such interactions may inactivate the protein, and additives must 
be used to protect the active protein site form the alginate polymer.  For example, when the 
anionic polymer poly (arylic acid) was added to the TGF-β1 alginate complex, the polymer 
shielded the TGF-β1 from interactions with the alginate, allowing the protein to retain full 
activity even while complexed with the alginate (Murnper, Hoffman et al., 1994). 
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Release of Matrix Encapsulated Particles  
There are two mechanisms of release associated with protein encapsulation in alginate 
matrices; diffusion of the protein through polymer network pores, and release of protein through 
polymer degradation.  
Diffusion 
Electron microscopy investigation has revealed the pore sizes of calcium alginate beads 
range in diameter from 5 to 200nm (Anderson, Skipnes et al., 1977).  Diffusion of small 
molecules is independent of the matrix, while diffusion of larger molecules, such as proteins, is 
dependent on the molecular weight of the alginate matrix.  Successful protein diffusion has been 
reported involving immunogloben G (Tanaka, Matsumara et al., 1984), and insulin (Gray and 
Dowsett, 1988).  Increasing the concentration of alginate within the beads can decrease the rate 
of diffusion of the protein from alginate beads.  As well, gels with higher α-L-gluronic acid 
blocks exhibit larger pore structures and produce the highest protein diffusion rates (Matinsen, 
Skjak-Braek et al., 1991).  In addition, the rate of the diffusion may be influenced by the charge 
on the matrixed protein.  A protein with a net positive charge will form interactions with 
negatively charged polymer and inhibit diffusion from the matrix (Mumper, Hoffman et al., 
1994). 
Degradation 
 As well, protein may be released from encapsulation following the degradation of the 
cross-linked alginate gel.  A chelating agent such as lactate, citrate, phosphate, or a high 
concentration of ions can be used to remove the cross-linking Ca2+ ions, resulting in the 
breakdown of the matrix gel (Sutherland, 1991).  This in turn will release encapsulated protein, 
and allow for protein solubility in surrounding environments. 
Release of Emulsion Encapsulated Particles  
The release of encapsulated drug from oil in water emulsions will occur when the 
emulsions are placed in another solvent medium through natural diffusion.  However, the rate of 
diffusion will vary greatly with degradation of the emulsions particles through various 
mechanisms of emulsion aging.  Although the use of polymer surfactant greatly reduces the rate 
and occurrence of the various forms of degradation, factors such as time, temperature, solubility, 
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density, viscosity and particle size will nevertheless have a strong influence on the rate of 
inevitable emulsion decomposition. 
Creaming & Sedimentation 
If there is a substantial difference between the densities of the droplets and the 
surrounding solvent, then creaming or sedimentation is likely to occur.   These are cases where 
the droplets will shift within the continuous phase as seen in Figure 5.  When the droplets are 
lower in density then the continuous phase, then creaming will result where the droplets float 
towards the surface of the solvent.  In contrast, if the droplets are higher in density than the 
continuous phase, then sedimentation will occur where the droplets will be pulled to the bottom 
of the continuous phase by gravity (Bibette, Roux et al., 1992).  
These processes can be prevented through the use of oil and solvent with similar 
densities, and through the use of increased amounts of continuous phase, resulting in smaller 
droplet size, and reducing the gravitational pull. 
Flocculation 
When droplet particles group together within the continuous phase, a phenomena known 
as flocculation occurs as observed in 
                                                 
3
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Figure 5.  Creaming & Sedimentation 3 
 14 
Figure 6.  The groups are formed as the result of electrostatic interactions, intramolecular 
forces, and hydrogen bonding, and occur independently of the densities of the phases.  This 
aggregation can be avoided through the use of a more viscous continuous phase fluid that will 
reduce the movement of droplets within the medium.  As well, flocculation may be avoided by 
altering the pH of the continuous phase to repel the droplets (Blijdenstein, Zoet et al., 2004).  
Flocculation does not involve coalescence, and therefore does not result in a change of particle 
size. 
Coalescence 
When flocculation occurs it is possible for the films that separate the droplets to rupture, 
resulting in the joining of droplets and an increase in particle size.  This is referred to as 
coalescence as can be observed in Figure 7.  Coalescence often occurs in the absence of or with 
an inadequate amount of surfactant.  After a period of time, coalescence will result in the 
complete disassociation of the droplets, and the two phases will separate more distinctly.  
Coalescence cannot occur without flocculation, so if flocculation can be prevented than 
coalescence should not be a concern.  As well, the proper use of an emulsifying agent, such as 
                                                 
4
 (Correia et.al, 2005)  
5
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Figure 6.  Flocculation 4 
 
Figure 7.  Coalescence 5 
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alginate polymer, will ensure stabilization of the particles and lower interfacial tensions, greatly 
reducing the threat of coalescence (Imbert, Satdler et al., 2002). 
Ostwald Ripening 
When droplets begin to increase and decrease in size they will eventually begin to 
dissolve into the continuous phase.  This is referred to as Ostwald ripening, and is a result of the 
Kelvin-Thompson effect where the solubility of the dispersed phase increases through the 
continuous phase as the interfacial curvature increases as can be observed in Figure 8 (Sadtler, 
Imbert et al., 2002).  Eventually as the size of the droplets change, the small droplets disappear 
and the larger droplets become so great in diameter that the interfacial energy of the emulsion is 
affected and the droplet eventually breaks down.  Ostwald ripening may be avoided by using a 
dispersed phase that is insoluble in the continuous phase. 
Biological Properties of Alginate 
When researching a polymer for use in drug delivery applications it is necessary to fully 
investigate its immunogenicity and biocompatibility to ensure that it will be fully accepted by the 
physical system. 
Immunogenicity 
Research into the immunogenicity of alginate polymer has brought together a consensus 
that the chemical composition and the mitogenic contaminants found in alginate are the two main 
reasons for reported immunogenicity.  Alginate polymer comes in many different grades 
commercially, including food or research grade and ultra-pure medicinal grade.  It has been 
                                                 
6
 (Correia et.al, 2005) 
 
Figure 8.  Ostwald Ripening6 
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shown that the impurities found in commercial alginate are responsible for the side affects 
observed, including cytokine release and inflammatory reactions (Zimmerman, Klock et al., 
1995).  However it is also proven that pure alginate does not contain these impurities and 
therefore does not induce any side effects.  In addition, researchers have proven that there is a 
correlation between the level of mannuronic acid blocks and cytokine production (Otterlei, 
Ostgaard et al., 1991), therefore it is recommended that pure alginate rich in α-L-gluronic acid is 
used for in vivo research to avoid inflammatory reactions (Spargo, Rudolph et al., 1994). 
Further research into the use of alginate as surgical gauzes and films reports full 
biodegradability of the polymer in animal tissues with very little reaction (Blaine, 1947).  As 
well, when used as implants, alginate high in α-L-gluronic acid has proven to produce less of an 
immunological response then polyvinyl alcohol and agarose gels (Spargo, Rudolph et al., 1994).  
Moreover, investigations involving implantation of high α-L-gluronic acid alginate into the 
upper nasophrynx of mice produced little or no inflammatory response, making alginate a very 
promising drug delivery agent for mucosal delivery (Schuh, Fanslow et al., 1996). 
Bioadhesion 
Alginate polymer has a very strong bioadhesive property, which again makes it a viable 
candidate for mucosal delivery.  With carboxyl end groups, alginate is classified as an anionic 
mucoadhesive polymer.  Research has shown that polymers with charge density are strong 
mucoadhesive agents (Chickering, Jacob et al., 1995).  It is believed that penetration of the 
polymer chain across a polymer-mucosa interface is responsible for the great adhesion (Jabari, 
Wisniewski et al., 1993).  Alginate has proven to have the greatest mucoadhesive strength when 
compared with other polymers including polystyrene, chitosan, carboxy-methylcellulose, and 
poly (lactic acid).  Alginate’s strong bioadhesive properties will serve to localize the drug upon 
release, and therefore would potentially improve the overall drug effectiveness with mucosal 
delivery. 
Possible Applications of Alginate Polymer Controlled Drug Release 
Systems 
There are numerous possible applications of alginate polymer drug delivery systems 
using both encapsulation with matrices and encapsulation with alginate surfactant oil in water 
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emulsions as delivery agents.  Primarily, there is an increasingly strong market for vaccines to 
numerous pathogens, and the traditional perenternal delivery route for these vaccines has proven 
ineffective when treating against airborne or mucosal-related respiratory diseases (Mestecky, 
1987). 
Immunologists have recognized the potential of immunizing using the mucosal surfaces, 
where the protective antibody, secretory immunoglobulin A (IgA), is produced (Mestecky, 
1987).  As alginate exhibits strong bioadhesion and biocompatibility for mucosal use, it is an 
ideal candidate for mucosal vaccine and other drug delivery developments designed for the upper 
respiratory tract.  In addition, the slow release mechanism of alginate matrices has proven very 
successful, and is potentially very useful for the release of therapeutic proteins.  Several studies 
have proven the in vitro and in vivo efficacy of slow alginate matrix drug release. 
Moreover, investigations have been made into the encapsulation and release of other 
materials, including DNA, microspheres, and liposomes.  The successful encapsulation of DNA 
has been observed, and release was achieved at pH 6.5 without denaturation of the DNA 
molecule.  There is potential to use this delivery method to target nucleic acids as agents in gene 
transfer (Smith, 1994).  In addition, alginate beads were prepared with encapsulated 
microspheres by dispersing the microspheres in an aqueous solution of sodium alginate, and 
dropping the resulting solution in a cross-linking CaCl2 bath.  This has potential for an oral 
delivery system of micro- and or nanoparticles (Bodemeier, Chen et al., 1989).  As well, 
liposomes have also been successfully encapsulated in alginate spheres after coating with 
phospholipase C, D, or A2, and subsequent release was triggered by the enzymatic degradation of 
the phospholipids by the phospholipases at 37°C.  It is believed that by altering the 
phospholipase used to coat the liposomes, the release of the liposomes may be controlled (Igari, 
Kibat et al., 1990). 
Overall, there have been many promising investigations into various potential methods of 
alginate drug delivery, and due to its high biocompatibility and bioadhesive properties, alginate 
is an ideal candidate for further investigation. 
 18 
Methodology 
Alginate Synthesis 
The modified alginate that was used in all experiments was prepared using the following 
method.  A solution of 10g AANa (sodium alginate) in ethanol (70%) with 10 ml HCl (37%, 
12N) was stirred in an ice bath at 4°C for 30min, then filtered, washed with 2L ethanol (70%) 
and 0.5L acetone.  The product was dried in a vacuum for 2hrs, and redissolved in 0.5L H2O.  
TBA OH (0.15M) was then titrated into the alginate solution until a neutral pH of 7.0 was 
achieved.  The solution was very viscous during the first steps of titration, but became much 
more manageable with the increase in pH.  The resulting solution of AATBA was divided into 
five flasks, frozen, and lyophilized for 2 days.  The product was collected and massed at 15.31g, 
a 75% yield. 
The 15.31g AATBA was dissolved in 1L of DMSO and left to stir vigorously for 24 
hours to ensure complete dissolution.  To the dissolved solution of AATBA (15.31g, 700ml 
DMSO) 1-Bromo-dodecane (0.7536g, d1.04, Equation 1) was added in a 2 ml DMSO solution 
and washed with another 2ml DMSO as represented in Figure 10 Alginate Synthesis: Addition of 
1-Bromo-dodecane.  Solution was allowed to stir overnight at a constant temperature of 25.5°C 
at 370 tr/min. 
COO-Na+
COO-Na+
EtOH 70%
HCl 0.6N
Mix, 30min
      4C
COOH
COOH
1) Filter, wash 
EtOH 70%, Acetone
2) Neutralize with TBOH
Lyophilisation
COO-TBA+
COO-TBA+
 
Figure 9.  Alginate Synthesis 
COO-TBA+
COO-TBA+
1) DMSO
24hr mixing
2) C12Br
24hr mixing
COO-TBA+
OO
 
Figure 10 Alginate Synthesis: Addition of 1-Bromo-dodecane 
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A solution of NaCl (96ml, 2.5M) in H2O was added to the alginate after 24hrs as 
represented in Figure 11.  This was done to replace the existing TBA+ ions with Na+.  Alginate 
was in a strong gel state and would not mix with Na+ solution, so mixture was remounted to stir 
for 2hrs.  Afterwards, 675 ml of EtOH (70%) was added to the solution and agitated for 15min.  
Alginate was then washed in two separate runs with 4L EtOH (70%), 2L acetone, and dried in a 
drying oven at 25°C.  A small sample of alginate was tested for solubility in water at a 
concentration of 5mg/ml after 24hrs of agitation. 
Polymer Characterization 
Various concentrations of C12OH in Toluene were analyzed against a stock solution of 
C14OH (5 mg/ml) to produce a calibration curve that was used to determine the substitution rate 
of alkyl chains on the alginate polymer.  A stock solution of C14OH (5 mg/ml) and toluene was 
prepared and left to stir for 24 hrs.  Five solutions of various concentrations of C12OH in the pre-
made stock solution were then prepared at concentrations of 1 mg/ml, 2 mg/ml, 4 mg/ml, 6 
mg/ml, and 8 mg/ml were also prepared a day in advanced and left to stir for 24 hrs.  On the day 
( )[ ]19810041704.1
102499.0 3
×−+××
××××
=
αα
βmV  
m: mass of AATBA = 15.31 
∝: percentage of acidic functions = 70 
β: rate of chain fixing = 8 
 
Equation 1.  Volume of 1-Bromo-dodecane to add 
for a certain rate of alkyl chain addition 
1) NaCl (96ml, 2.5M) in H20
2) EtOH (675ml, 70%)
3) washed 4L EtOH (70%)
2L acetone, dried at 25*C
COO-Na+
OO
COO-TBA+
OO
 
Figure 11.  Alginate Synthesis (continued) 
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of analysis, a solution of 100 mg alginate in 1ml NaOH solution (4N) and 4 ml H2O was 
prepared.  The solutions of C12OH at various concentrations were analyzed with Gas 
Chromatography on a GC-17A Shimodzu Gas Chromatograph. 
Analysis of Chemical Properties of Lidocaine 
In order to optimize the drug encapsulation and release kinetic tests with our alginate 
polymer, it was first necessary to test various properties of the model drug.  The structure of 
lidocaine was chosen for the kinetics experiments because of its aromatic ring that readily 
absorbs electromagnetic radiation as represented in Figure 12.  The high detectability of this ring 
with UV made lidocaine an ideal drug for monitoring drug release kinetics.  We made a careful 
analysis of lidocaine in a dilute NaOH solution (10-4M) to determine the extinction coefficient, ε, 
the measure of how well the molecule absorbs electromagnetic radiation at a certain wavelength 
as used with Ultraviolet-Visible Spectroscopy.  The use of a dilute NaOH solution, of pH 10, is 
due to the fact that lidocaine is very sensitive to changes in pH.  For this reason, it was important 
to maintain a stock solution of NaOH at pH 10 that had to be monitored and adjusted daily to 
maintain accuracy.  The extinction coefficient is required to perform further concentration 
calculations with Beer-Lambert’s Law, an experimental relationship that relates the absorption of 
light to the medium through which that light is traveling. 
This law is the basis behind the use of spectroscopy to identify substances, and is 
represented by Equation 2.  In this equation, A represents the absorbance, ε is the extinction 
coefficient, l is the distance that the light travels through the material and is equal to the length of 
the cuvette, and c is the concentration of absorbing species in the material.  Essentially, the law 
states that there is a direct dependence between the concentration of a substance and the 
 
Lidocaine 
2-(diethylamino)- 
N-(2,6-dimethylphenyl)acetamide 
Figure 12.  Lidocaine chemical structure 
 21 
absorbance of light in the substance, as well as the length of material that the light travels 
through.  Therefore, if the variables l and ε are known, the concentration of the substance can be 
calculated from the amount of light that is absorbed.  
Extinction Coefficient Determination 
To determine the extinction coefficient of lidocaine, a plot of the concentration of 
lidocaine in solution versus its absorbance was required.  The plot would be linear for lidocaine 
concentrations less than 1 g/L and the slope of the line would be the extinction coefficient since 
the length of the cuvette was 1cm.  A stock solution of approximately 1 g/L lidocaine in 10-4 M 
NaOH was prepared for the analysis.  The exact amount of lidocaine and 10-4 M NaOH used to 
make the solution were weighed using a precision scale to determine the exact concentration of 
the solution as weighing is more accurate than measuring by volume as long as the density of the 
solution is known.  Since 10-4 M NaOH is very dilute, the density was assumed to be equal to 
water.  In this case, 0.026 g of lidocaine was combined with 25.755 g of 10-4 M NaOH solution 
to obtain a lidocaine solution of 0.999 g/L.  The solution was allowed to stir overnight to ensure 
that it was completely dissolved before UV spectroscopy tests were performed. 
Before the UV spectrophotometer could be used, it had to be calibrated.  The 10-4 M 
NaOH solution was used as the baseline calibration for the machine.  A spectrum scan was then 
run to on the NaOH solution to verify that no light was absorbed at all wavelengths.  Once the 
machine was calibrated, the stock solution of lidocaine was taken and three additional dilutions 
were made so that the approximate concentrations of the solutions were 0.25 g/L, 0.5 g/L, 0.75 
g/L and the original 1 g/L.  Each of these dilutions was prepared using the precision scale so that 
the exact concentration of each was known.  Each solution was then run through the UV 
spectrophotometer and the absorbance at the peak of each spectrum scan, corresponding to a 
wave length of 262nm, was recorded.  Each absorbance was then plotted against its respective 
concentration and a trend line was added, giving the slope of the line and thus the extinction 
coefficient of lidocaine. 
clA ⋅⋅= ε
 
Equation 2.  Beer-Lamberts Law 
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Solubility of Lidocaine 
Once the extinction coefficient had been determined, UV spectroscopy could be used to 
determine the solubility of lidocaine.  Approximately 1g of lidocaine was placed in 100 mL of 
10-4 M NaOH solution and allowed to stir overnight.  Then the lidocaine solution was 
centrifuged to collect the undissolved lidocaine so that the saturated lidocaine solution could be 
removed.  The concentration of the saturated lidocaine solution was assumed to be greater than 1 
g/L and thus it needed to be diluted for UV analysis.  A one to six dilution ratio was chosen and 
both the amount of saturated solution and 10-4 M NaOH solution added were weighed using the 
precision scale.  The diluted sample was then analyzed using UV spectroscopy and the 
absorbance was recorded.  Using the extinction coefficient previously determined, the 
concentration of the sample was less than 1 g/L and no further dilution was needed.  The actual 
saturation concentration of the lidocaine was then back calculated based on the amount the 
sample was diluted. 
Partition Coefficient (Kp) 
The partition coefficient, Kp, is the measure of differential solubility of a compound in 
two immiscible solvents.  Kp is defined as the ratio of the concentration of the solute in one 
solvent to its concentration in the other solvent, as represented in Equation 3.  The standard 
method for Kp determination is the shake-flask method, where a known amount of substance is 
dissolved in a known volume of either solvent.  After mixing well and allowing adequate time to 
reach equilibrium, the concentration in one of the solvents is recorded using UV spectroscopy.  
In this case, the goal was to determine the partition coefficient for lidocaine in oil versus in a 
dilute solution of 10-4 M NaOH. 
Two different approaches were used for this experiment.  In the first trials a known 
amount of lidocaine was dissolved in the NaOH solution at a concentration close to the 
saturation value (about 4 mg/mL).  This aqueous lidocaine solution was mixed with four 
different clean oils:  dicaprylyl carbonate, caprylic/capric triglyceride, octyldodecanol, and 
aqueousin  lidocaine
oilin  lidocaine
C
C
K P =  
Equation 3.  Partition Coefficient Determination 
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miglyol.  Three trials were performed using different volume ratios of oil to aqueous and 
different total volumes. 
1) 3:5 (oil:aqueous), 4 mL total 
2) 3:5 (oil:aqueous), 10 mL total 
3) 1:1 (oil:aqueous), 10 mL total 
In each case, the samples were mixed well overnight and allowed to settle until the 
phases were visually separated.  In the second trials, the lidocaine was dissolved in oil (6 
mg/mL) and mixed with the pure NaOH solution at a ratio of 1:1 (oil:aqueous), 10 mL total.  
Like in the previous trials, the samples were shaken overnight, and then allowed to settle. 
In each case, the aqueous phase was analyzed using UV spectroscopy and the previously 
determined extinction coefficient in order to determine the resulting concentration of lidocaine in 
that phase.  Since the initial concentrations were known, the equilibrium lidocaine concentration 
in the oil could be calculated. 
It was very important that the lidocaine was given adequate time to dissolve in the 
primary solvent before the second solvent was added to the solution. In addition, it was 
necessary to thoroughly disturb the oil and water mixture with a stir bar to ensure that the drug 
had adequate time to move between phases.  Likewise, it was equally important to let the two 
phases separate afterwards to ensure that only the aqueous phase was removed for UV analysis.  
Oil Purity 
There were four oils available for drug encapsulation studies and it was necessary to 
investigate the purity of the oils in addition to the partition coefficients to determine the oil most 
suitable for emulsification.  The purity of the oils has a strong affect on emulsion preparation and 
stability, so the cleaner the oil the better the emulsification procedures and analysis will run.  In 
order to determine the purity of the oils, small amounts of each oil (5ml) was washed three times 
with the dilute NaOH solution, then on the third washing samples of the aqueous solution were 
tested with UV to determine purity.  The pure oils would reveal clean NaOH solutions, while the 
aqueous from the still impure oils would give unwanted peaks against the baseline NaOH.  The 
four oils under investigation were dicaprylyl carbonate, caprylic/capric triglyceride, 
octyldodecanol, and miglyol.  The miglyol and the caprylic/capric triglyceride proved to be the 
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least pure out of the four chosen, while the dicaprylyl carbonate was the second purest and 
octyldodecanol was the purest oil tested.  Based on the partition coefficient results and the oil 
purity results, it was determined that octyldodecanol was the most suitable oil for 
experimentation, and a large volume (300 ml) was washed three times with the dilute NaOH 
soultion to ensure purity. 
Emulsions 
Emulsion preparation was a major part of the investigation, as alginate emulsions had not 
yet been closely investigated by ENSIC and the optimal conditions for emulsification were 
unknown.  Therefore, we attempted to form emulsions at a variety of concentrations and 
solvent/oil ratios to properly optimize the emulsification process.  This section outlines the steps 
for emulsion preparation, and the analysis of emulsions produced including particle size and 
stability. 
Emulsion Preparation 
A solution of lidocaine at a measured concentration was prepared the day before 
emulsification and stirred for 24hrs to ensure complete dissolution.  Emulsions were first 
prepared with concentrations ranging from 0.1mg/ml to 4mg/ml and tested for particle size and 
strength until an optimal concentration was found, as described in the results section.  The 
solution was then combined at a specific ratio of 10% to 30% oil to yield 10ml total, and the 
resulting oil/aqueous mixture was vortexed using a Yellow Line vortexer at a speed of 2500 rpm 
for a period of one minute.  The solutions were then ready for emulsification.  
Emulsification 
Emulsions were prepared by sonication with a Vibra-Cell emulsifier (Bioblock 
Scientific).  Sonication is a technique that irritates the solution with high frequency sound waves 
that increases the rate of reaction and stabilizes the oil/water mixture.  After the initial oil/water 
solutions were vortexed they were introduced to the sonicator device and the sonic probe was 
carefully inserted in the vial at the point of oil/water separation ensuring that it did not touch any 
sides of the surrounding vial, and the vial was fastened with a clamp.  The depth of probe 
insertion was recorded so that the same experimental conditions could be reproduced in future 
emulsifications.  A water bath was then placed around the vial to absorb the heat of the 
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anticipated reaction, and the sonication procedure was started.  The sonicator was adjusted for a 
time of 3 minutes with a 50% active cycle and a power level of 5, or approximately 100 W.  
These settings were kept constant through the remaining emulsification experiments. 
The intensive shock waves as applied during emulsification speed up the reaction rate of 
the oil/polymer solution, producing one homogeneous emulsified solution.  The solution 
produced was then ready to be investigated for particle size and stability. 
Particle Size Analysis 
Once the emulsions were prepared it was necessary to determine the size of the emulsion 
particles, as the aim was to optimize the emulsion procedure to produce the smallest and most 
stable emulsion particles possible.  The particle sizes were investigated using a Malvern 
Instrument High Performance Particle Sizer produced by Spectris Co.  This HPPS contains a 
Neon-Helium laser with a high sensitivity that overcomes the multiple angle scattering produced 
by the particles.  HPPS analytical equipment is capable of measuring particle sizes from 0.6 to 
6000 nm, and is able to minimize error from sources such as dust particles and occasional large 
emulsion droplets by taking readings at different angles within the cuvette. 
The emulsions samples were prepared by adding a drop of emulsion to approximately 
3ml of prepared NaCl (10-3M) solution, and mixed thoroughly with a pipette.  The vial was then 
inserted in the particle sizer and data was gathered as described in the results section of this 
report.  In accordance with the observed particle sizes, sizes for various emulsion were explored 
from 0.1 to 4.0mg/ml alginate concentration in both NaOH solution and 10-2 M NaCl solution, 
and in both 10% and 20% octyldodecanol mixtures.  The cuvette with the diluted emulsion 
samples was introduced into the HPPS after a warm up period of ten minutes, allowing the 
particle sizer to adjust to 25°C.  Once the proper temperature was reached the parameter settings 
were adjusted as outlined in Appendix A1.  Once the settings were optimized, the cuvette 
samples were run 3 times, with each run involving between 8 and 20 various sub-measurements.  
These measurements were then averaged out and the average particle size and polydispersity 
values, or the range of particle size in solution, for each sample were obtained.  The emulsions 
prepared which retained relatively small particle sizes and decent polydispersity values over a 
period of a couple days were then tested for stability. 
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Emulsion Stability 
The stability of the emulsions was investigated through both lyophilization and 
centrifugation, and the sizes of the emulsions were re-measured after disturbance.  Primarily, 
lyophilization allows for the drying of a specific sample without changing the structure.  A small 
amount of the emulsion (1 ml) was placed in a 5 ml plastic tube, and a collection of these plastic 
tubes were bound together and immersed in liquid nitrogen.  When the emulsions inside the 
tubes were completely frozen, the bundle was then put into a larger flask that was then connected 
to the lyophilizer and allowed to freeze-dry for 48hrs.  Lyophilization itself involves the 
vacuuming of the solvent at a low temperature, entirely avoiding high temperatures that might 
interfere with chemical structure.  This method is used often in organic chemistry as it 
successfully removes solvent, leaving only the desired chemical compound that can then be 
processed and stored as desired.  However, with our investigations the lyophilized emulsions 
were then reconstituted in 1 ml MilliQ water, and sonicated to ensure complete dissolution 
before they were tested again for particle size. 
In addition, centrifugation was also used a method to test particle stability.  Samples of 
promising emulsions were placed in centrifuge tubes and centrifuged at 110 g for 10 min.  These 
samples were then investigated for oil/water separation, but fortunately no separation was 
observed.  The centrifuged samples were then also tested for particle size, and all data was 
recorded. 
The methods of lyophilization and centrifugation were both used to test against 
coalescence of the emulsion particles, and emulsion which were able to retain their former 
particle size after freeze drying and centrifugation were identified as promising, while only the 
optimal emulsions were chosen for drug release experimentation.  
Lidocaine Encapsulation 
After the conditions for emulsion preparation were optimized the experimentation with 
lidocaine encapsulation and release was started.  It had been determined that emulsions prepared 
with 1.4mg/ml alginate in NaCl (10-2 M) were the most stable, so three emulsions were prepared 
at the same concentration with the addition of 25mg/ml lidocaine in the octyldodecanol.  The 
emulsions were tested for particle size reproducibility, and then combined for lidocaine release 
analyses. 
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Lidocaine Release Kinetics 
Experiments were carried out to determine the volume of lidocaine released from the 
emulsion into an external solution.  As desired with drug release experiments, a release curve 
that maintained a constant rate of release after a certain period of time was desired.  In order to 
make proper calculations, a sample run of lidocaine in NaOH solution was tested, a solution with 
lidocaine and alginate was tested, and finally the lidocaine emulsions were tested for release rate 
into a dilute NaOH bath. 
In order to test the release kinetics of the various solutions, the emulsions were 
transferred into clean, washed membranes, which were then tied shut, rinsed, and submersed in 
the bath which was subjected to light stirring with a magnetic stir bar.  For samples, UV tests 
were carried out periodically on about 1.5 mL of the bath solution to determine the concentration 
of lidocaine and subsequently the release kinetics.  When samples were removed from the bath, 
they were later returned to the bath to maintain a constant volume. 
The lidocaine release test consisted of a 10 mL solution of 3mg/ml lidocaine in dilute 
NaOH.  This lidocaine solution was placed inside of a dialysis bag, which in turn was put in a 60 
mL bath of the base NaOH solution.  Samples were taken from the bath regularly, tested for UV 
absorbance, and then returned to the bath. 
A test of lidocaine and alginate (no emulsion) was performed to see if there was any 
difference in release simply from alginate being present.  For this experiment, a 10 mL solution 
was prepared containing 10-4M NaOH, 1.4 mg/mL alginate, and 2.5 mg/mL lidocaine.  The 
solution was placed inside of a dialysis bag, which was put in a 100mL bath of the dilute NaOH 
solution.  As described previously, samples were taken from the bath, tested for UV absorbance, 
and returned to the bath. 
The final test that was performed analyzed the release of lidocaine from an alginate-
stabilized emulsion.  The emulsion created for this test contained 25 mg/mL lidocaine in 
octyldodecanol which was combined with an aqueous solution consisting of 1.4mg/mL modified 
alginate in dilute NaOH and 10-2M NaCl.  The oil to aqueous volume ratio used was 1:9, as this 
yielded the best results from the emulsion stability experiments.  The emulsion was created as 
described previously in the section on emulsification.  In total, 30 mL of emulsion was placed 
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inside a dialysis bag, which was then put in a bath of 100 mL dilute NaOH solution.  Samples 
were taken in the same manner as the other release experiments.  
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Results and Discussion 
Rate of C12 Fixation 
The final modified alginate product was tested for the substitution ratio of C12 chains.  
The synthesis was performed with a goal of achieving an 8% substitution, although achieving 
this exact amount of substitution was not critical.  Instead, knowing what the actual substitution 
ratio attained was most important.  Several samples of C12H25OH in the base solution of 
C14H29OH and toluene, for which the concentration of  C12H25OH was known were run through 
the GC.  The ratios of C12 peaks to C14 peaks were recorded, and the concentrations of C12OH in 
the samples were plotted against these ratios to obtain a calibration curve, as in Figure 13.  The 
important thing to take from this calibration curve is the slope, which represents how the 
concentration of C12 chains varies with results from the GC.  A good correlation was achieved 
between these points, yielding a slope of 4.551. 
With the calibration curve, one can calculate the ratio of substitution of C12 chains on a 
sample of modified alginate using Equation 4.  This equation gives the rate of fixation of C12 
chains as a percent.  In the equation, c is the slope from the calibration curve in Figure 13, and 
msample is the mass of the alginate sample in mg.  MAA and MC12H25OH are the molecular weights of 
the sodium alginate and the dodecanol, respectively.  Finally, rsample and r1mg/mL are the ratios of 
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Figure 13.  Calibration curve for substitution ratio determination 
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the C12 areas to the C14 areas on the GC for the alginate sample and the 1mg/mL sample, 
respectively.  Plugging the values into the equation gives a rate of C12 fixation of 5.3%.  This is 
slightly lower than the target of 8%, however knowing the actual rate is more important. 
Extinction Coefficient Determination 
The extinction coefficient for lidocaine in 10-4M NaOH was determined in order to make 
use of UV absorbance readings in later experiments.  The dilutions of lidocaine of known 
concentrations were tested for UV absorbance over a range of wavelengths.  The lidocaine 
spectrum yielded a peak at 262nm, so the absorbance at this wavelength was used for all future 
readings.  By plotting absorbance versus the concentration of lidocaine times the length of the 
cuvette, a straight line was achieved as in Figure 14.  According to Equation 2, the slope of this 
line is the extinction coefficient, ε.  After plotting a line of best fit, the extinction coefficient was 
calculated to be 1.8023 L g-1 cm-1, which is consistent with literature values. This value was used 
for all subsequent calculations to determine the concentration of lidocaine solutions using UV 
spectroscopy.  
( )
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Figure 14.  Calibration curve for extinction coefficient at 262nm 
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Partition Coefficient (Kp) 
The first set of partition coefficient trials tested each of the four available oils for the best 
Kp value.  Using a near-saturated lidocaine in NaOH solution and a known amount of each oil, it 
was determined that octyldodecanol clearly had the best partition coefficient in each case; 
however, the Kp values obtained from each oil were inconsistent in each case.  Figure 15 shows 
the partition coefficients obtained using each oil under different conditions.  Since only one 
sample was performed with each oil at each condition, there is no experimental error information 
available. 
Although a definite value of the partition coefficients for lidocaine in each oil cannot be 
determined due to the variation in results, an important trend is noticed.  In every condition, 
octyldodecanol has the highest partition coefficient, despite ranging from 39 to 84.  As a result of 
this, we were able to focus further experiments on octyldodecanol alone, and disregard 
dicaprylyl carbonate, caprylic/capric triglyceride, and miglyol. 
The next set of trials, which used 6 mg/mL lidocaine in oil and the dilute NaOH solution, 
used only octyldodecanol as the oil.  This was done, given that we knew from the first set of 
trials that octyldodecanol was the best oil; however, a more accurate value for the partition 
coefficient was desired.  For this set of trials, the samples were duplicated four times to check for 
reliability.  The results were much more consistent in this case, yielding a Kp of 62 ± 3. 
The wide variation in Kp values for each oil under different conditions was unexpected.  
Theoretically, it should not matter how much of each phase is used and in what proportions they 
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are combined.  Some reasons for this variation could be that the smaller volume used (4 mL 
total) may have affected the UV readings, as there was only 2.5 mL of aqueous phase available 
to use in the sample cuvettes.  This small sample size could have made a big difference if some 
of the oil was retained on the pipette and was mixed with the UV sample.  Another possibility is 
that different stock solutions were used for the saturated lidocaine in the dilute NaOH solution 
for different cases.  This could have been a problem, as obtaining a consistent reading for the 
saturation concentration of lidocaine proved to be difficult, and was highly temperature and pH 
dependant. 
Emulsion Stability 
As mentioned previously, we tested many types of emulsions for stability by measuring 
particle sizes over time using the HPPS.  Unlike with other polymers such as modified dextran, 
researchers at ENSIC did not have a great deal of experience with creating modified alginate 
emulsions.  For this reason, we varied the properties of the emulsions greatly, from 0.1 to 
4.0mg/ml alginate in the aqueous and from 10% to 30% octyldodecanol by volume.  The goal 
was to find an emulsion that exhibited both stability over time and an ideal average particle size. 
The first step was to determine the best fraction of oil to be used in emulsions.  
Emulsions were created of 10, 20, 25, and 30% oil, at a variety of alginate concentrations.  The 
initial average particle sizes for each of these emulsions is shown in Figure 16.  From the plot, it 
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is clear that in general, emulsions made with 10% oil were much smaller initially than emulsions 
of other oil fractions.  Because of this, subsequent emulsions were made with 10% oil by 
volume.  It was suggested that a dilute ionic solution of 10-2M NaCl be used in the aqueous 
phase along with the alginate and NaOH.  The reason for this is to help balance the slightly 
positive charge of the alginate polymer in hopes of further stabilizing the emulsions.   
Since the emulsion containing 10% oil, and 1.4 mg/mL alginate provided the smallest 
initial particle size out of the first set of emulsions, the next set of emulsions were created with 
polymer concentrations around this amount in hopes of finding the best concentration for 
emulsion size and stability.  The next set of emulsions were tested at different time intervals in 
order to get an idea of stability of size over time.  Additionally, the samples were lyophilized and 
reconstituted, as well as centrifuged in order to further examine their stability properties.  A plot 
of the resulting sizes is shown in Figure 17.  As in the previous set of measurements, the smallest 
size for emulsion particles resulted from the 1.4 mg/mL alginate concentration in an emulsion of 
10% oil.  This emulsion also showed the best stability over time, remaining the smallest over 
time.  Although the emulsion particles grew from 517 nm at 12 hrs to 614 nm at 38 hrs, the 1.4 
mg/mL emulsion was clearly the most stable over time. 
When looking at the particle sizes after centrifugation and after reconstitution from being 
freeze dried, an interesting change is noted.  In these cases, the 1.4 mg/mL emulsion actually has 
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Figure 17.  Stability of 10% oil emulsions over time 
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the largest particle size of the three samples.  This indicates that the 1.4 mg/mL emulsion may 
not be the most stable over time, however any decisive conclusion would not be possible, since 
only one emulsion was made of each type, limiting the availability of experimental error data.  
Because the 1.4 mg/mL emulsion (in 10-4M NaOH, 10-2M NaCl), with 10% octyldodecanol, 
consistently showed the smallest initial particle size, and the best stability over time, it was 
chosen as the best emulsion to continue ahead with drug encapsulation. 
The conditions for determining the best alginate emulsion to proceed with were not ideal.  
Both a lack of time and equipment availability made a complete and detailed investigation of 
emulsion stability impossible.  While we believe the best attempts were made to find what 
emulsion parameters would create the smallest and most stable emulsion, we are not certain that 
the 1.4 mg/mL, 10% oil emulsion is the best.  Even with the best particle size being achieved at 
517 nm, this is still too large for use in the body.  Ultimately, we would like to create a stable 
emulsion at about 300 nm or smaller to avoid problems with getting through capillaries. 
Lidocaine Encapsulation 
The creation of an emulsion containing lidocaine for use in release kinetics tests was 
done using 1.4 mg/mL alginate in dilute NaOH and NaCl.  The oil, once again octyldodecanol at 
10% total emulsion volume, contained the lidocaine at 25 mg/mL.  Three emulsions of 10mL 
each were created and tested for size.  Surprisingly, these emulsions encapsulating the lidocaine 
yielded the best particle sizes out of all emulsions created, with an average initial particle size of 
466 nm and a standard deviation of 13 nm. 
Lidocaine Release Experiments 
We performed release experiments to understand how the rate of lidocaine release from a 
polymer stabilized emulsion compared to a solution of lidocaine and a solution of lidocaine and 
modified alginate (no emulsion).  This testing showed how an alginate stabilized emulsion could 
be used to provide controlled drug delivery in an intravenous application.  The model we used 
assumed that the main mechanism for drug release was molecular diffusion.  We took the results 
of concentration of lidocaine in the bath and plotted them versus time as seen in Figure 18. 
The lidocaine release experiments proved to give very interesting and compelling results.  
With the exception of a few scattered data points, the release curves for just lidocaine and for 
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lidocaine and alginate line up almost exactly.  This is as expected, since the alginate is not 
encapsulating or in any way inhibiting or controlling the release of the lidocaine.  This also 
indicates that the alginate is not escaping from the dialysis bag and influencing the UV 
absorbance reading. 
The release kinetics for the alginate emulsion follows exactly the predicted trend.  There 
is a quick initial increase, corresponding closely with the plain lidocaine and the lidocaine and 
alginate experiments.  This is due to any unencapsulated lidocaine that is free in the aqueous 
phase of the emulsion, which is expected due to an equilibrium distribution of lidocaine between 
the oil and aqueous phase that is reached prior to emulsification.  After approximately 50 
minutes however, there is a noticeable change in the release kinetics for the emulsion.  At this 
point the release of lidocaine is nearly constant, indicated by the linear trend in the concentration 
over time. 
These results indicate that the alginate stabilized emulsion is quite effective in controlling 
the release of lidocaine when compared to free lidocaine which is simply diffusion controlled 
and follows first order release kinetics.  There are a number of things to consider, however, when 
look at these results.  First of all, only one trial was performed for each case, meaning that 
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information pertaining to experimental error is unavailable.  Time restraints and equipment 
availability became an issue and prevented further trials to confirm these results.  Second, it 
would have been better to continue the data collection for a longer period of time; however, the 
use of a dilute NaOH solution for the bath prevented this.  Maintaining a pH of 10 over the 
course of the experiments proved to be difficult because of the number of times the experiment 
needed to be uncovered for the removal of samples, which allowed the pH to drop slightly over 
the day.  The sensitivity of lidocaine to pH made it impossible to obtain accurate UV spectra for 
the lidocaine as the pH dropped. 
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Conclusions and Recommendations 
The objective of this study was to investigate the use of modified alginate as a surfactant 
for oil in water emulsions.  Our main goals were to synthesize some hydrophobically modified 
alginate by fixing C12 chains to the alginate backbone, and then to use that modified alginate to 
study its effect on the stability and size of emulsions as well as its impact on the release lidocaine 
from those emulsions.  The modified alginate was successfully synthesized and a rate of fixation 
of C12 chains of 5.3% was achieved.  We also performed several tests to determine the purity of 
various oils, and then found the partition coefficients for lidocaine in those oils versus the 
aqueous phase of dilute NaOH.  It was determined that not only was octyldodecanol the cleanest 
oil to start with, but it also had by far the highest partition coefficient for lidocaine with a Kp of 
62 ± 3. 
Once octyldodecanol was chosen as the best oil, a series of experiments were conducted 
to find the ideal parameters for emulsion formation with modified alginate.  Things to keep in 
mind were average particle size, as well as emulsion stability.  Emulsion stability was tested by 
making size measurements over time as well as by centrifuging and lyophilizing then 
reconstituting samples of the emulsions.  Results for stability were not conclusive, however it 
was determined that emulsions of 10% octyldodecanol by volume, and 1.4 mg/ml modified 
alginate in the aqueous phase of 10-4M NaOH and 10-2M NaCl, provided the best stability over 
time as well as the smallest average particle sizes.  When 25 mg/mL lidocaine was encapsulated 
in the oil, the resulting emulsions had very consistent size results, forming emulsions with an 
average size of 466 nm. 
The lidocaine release tests were the most promising results obtained, yielding exactly 
what was desired from the alginate stabilized emulsion.  After an initial quick release of 
lidocaine, the emulsion released lidocaine at relatively constant rate.  The trials in which 
lidocaine was not contained in an emulsion resulted in a quick initial release of the drug which 
soon leveled off, indicative of first order release kinetics. 
While the results obtained show that modified alginate does have potential as a candidate 
for stabilizing emulsions for controlled drug release, it should be noted that further studies need 
to be performed with the alginate.  A significant time restraint, as well as the unavailability of 
equipment when needed considerably limited the number of experiments that we were able to 
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perform.  Some recommendations include performing a more in-depth investigation into the 
optimum parameters for creating modified alginate emulsions.  With the right combination of 
factors, smaller and more stable emulsions can probably be created.  In addition, the lidocaine 
release tests should be duplicated, in order to confirm our findings.  It should be noted, however 
that a means of stabilizing the pH of the NaOH solution should be considered, as the UV 
absorbance of lidocaine is very dependant on pH. 
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Appendix A: Equipment and Experimental Procedure 
A.1. High Performance Particle Sizer (HPPS) 
Malvern Instruments Ltd., United Kingdom 
Microsoft Windows 2000 software 
Software Set Up 
 Before the emulsions were run in the HPPS machine it was necessary to create a Standard 
Operating Procedure (SOP) to establish a set of parameters for emulsion investigation. It is 
important to use an SOP to ensure that all emulsions are measured in the same way without 
having to repeatedly set up the procedure.  
 To create and SOP, open the HPPS program called Dispersion and select New SOP in the 
Configure menu. The Size measurement type was then chosen since it also measures Protein 
Melting Point, Zeta Potential, Molecular Weight of the sample and trend. After selecting the type 
of measurement a sample name must be selected, and general notes can also be included. It is 
important to check on the box that says Show this page when the SOP is started to allow 
changes in the name of the emulsion and modification of any comments made with previous 
samples.  
 In the next screen the type of cell or cuvette that will be used with this equipment must be 
specified since the accuracy of the measurements can vary significantly depending on the 
material that the cell is made of. During this project a DTS0012-Disposable sizing cuvette was 
chosen. The following table summarizes the properties of this type of cell. 
Table 1: Choosing the correct (Size measurements) adapted from Zeta Nano Series User 
Manual, p 4.4 
 
Disposable Polystyrene (DTS0012) 
Typical Solvent Water, Water/Ethanol 
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Optical Quality Good to very good 
Minimum Sample Volume 1mL 
Advantages Low cost 
Single use disposable (No cleaning 
necessary) 
Disadvantages Not resistant to organic solvents 
Unsuitable for use at high 
temperatures (Above 50ºC) 
  Once this type of cell is chosen the software determines the conditions of measurement 
for that cell type, i.e. cell position.  
 After clicking on Next, the sample settings have to be specified. During this investigation 
only sample settings for size determination were set. The first step is to determine the material 
and dispersant properties. In order to do so, the Dispersant tab must be selected which provides 
us with a list of all the possible dispersants for that type of cell, such as decane, toluene and 
water among others. Water was selected as our dispersant material for this project. 
 The next step was to set up the measurement properties. A temperature of 25ºC was 
specified to keep our sample at room temperature during. The type of measurement duration was 
set to Automatic, allowing the equipment to perform the same test with all the samples and 
avoid variance in the measurement parameters. By setting the measurement duration to 
automatic the measurements were divided into a number of runs of at least 10 seconds in length. 
For accuracy of results, the number of measurements was set to 3 which this allowed us to 
confirm how well the solution was mixed after being diluted.  
Sample Measurements 
 Once the SOP file has been created and all the measurement properties for particle size 
have been set the HPPS was ready to take measurements. After turning the HPPS on it was 
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important to let the machine stabilize for about 30 minutes before starting the first run so the 
machine could reach room temperature and provide more accurate results. To prepare the sample 
two or three drops of the emulsion were placed into the disposable cuvette. The sample was then 
diluted with MilliQ water. It was important to fill the cuvette at least 10mm from the bottom of 
the cell since the HPPS starts measurements 8mm from the bottom of the cuvette.  
 Once the sample was diluted the cell was placed into the particle sizer and it was left 
undisturbed for at least 10 minutes so the sample could properly settle. The Start SOP is 
selected from the measure menu, which will bring up all the available files. After selecting the 
SOP file name that was given previously, the sample was ready to be measured by pressing the 
Start key. The system starts the measurement by setting the number of runs and by attenuating 
the index.  
 While the sample is running it is possible to observe the quality of the sample through the 
Count Rate and the Correlation tabs. Dust will be represented by sharp spikes in the Count 
Rate. The quality of the sample is easily observed under the correlation tab since this provides a 
plot that helps to interpret any problems with the emulsion. Figure 32 is an example of how to 
differentiate between a contaminated sample and a normal one. 
 
Figure 19: Correlation Function 
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 Once the sample run is finished, results by intensity as well as by volume can be 
obtained. For accuracy during this project all the results reported are based by intensity. Figure 
20 shows the equipment used to determine the average particle size of most of our emulsions. 
 
Figure 20: High Performance Particle Sizer 
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A.3. Emulsification 
Bioblock Scientific Vibracell 
Prolabo Adjusting Table 
 
 Solutions of alginate polymer in 10-2 M NaOH were prepared and left to stir overnight. 
Then a fraction of oil was added (10-20%), and the new solution was vortexed for 1 minute. It 
was then placed inside the sonicator box ensuring that the probe did not touch the sides of the 
tube, and rested at the interface of the oil/water phase separation. The tube was then fastened 
with a clamp to prevent movement during the sonication process. As well, an ice water bath was 
placed around the vial to absorb the heat produced during sonication.  
 The Vibracell box was then set up by adjusting the time setting to 180 seconds, and the 
active cycle setting to 50%, which means that the probe will send sound waves to the emulsion 
for one second every two seconds. The power setting was established by turning the knob to 5, 
representing a voltage of about 100W. Once all the settings were set, the wooden cabinet door 
was closed and the Marche button was pressed. Figure 21 shows the Bioblock Scientific 
Vibracell sonicator used during this project. 
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Figure 21 Sonication Box 
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A.4. Centrifugation 
Apparatus: 
Jouan GR 20 22 
 
The centrifuge is used to separate the desired product from the undesired solvent. The 
preparation of the centrifuge tubes is very important. There are six slots for the centrifuge tubes 
that were used. Opposite sides of the rotor must be equally balanced. In this specific centrifuge, 
the weight difference on opposite sides of the rotor must be within 50 mg of each other. If this 
weight difference limit is not obeyed, the machine can break. 
Place the centrifuge tubes in the rotor with the equal weight centrifuge tubes on the 
opposite side of the rotor. Then with the hand wrench lightly secure the lid. Excessive force is 
not necessary. Then close the hood of the centrifuge. Next set up the program desired. 
Programming: 
• Turn on the centrifuge with the switch located on the right side of the machine 
• Press 'Prog' 
• Output: "Numero Programme: _ _" 
• Press 11 then enter 
• Output: "Prog Numero 11 Exist" 
• Press enter 
• Output: "Rayon: _97mm" 
• Press enter 
• Output: "Duree/Int? (1/0): 1" 
• Press enter 
• Output: "Duree: _ _h_ _min" 
• Enter desired length to centrifuge then press enter 
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• Output: "Temperature: 25 C" 
• Enter desired temperature then press enter 
• Output: "Delta Temp: 0 C" 
• Press enter 
• Output: "Acceleration: _" 
• Enter desired acceleration (1-9) then press enter 
• Output: "Frienage: _" 
• Enter desired frienage (1-9) then press enter 
• Output: "Vit/NBG? (1/0): 1" 
• Press enter 
• Output: "Vitesse: _ _ _ _ _ Tr/mn" 
• Enter desired revolutions per minute (up to 18000) then press enter 
• Output: "Ecrire Sous Le No: 11" 
• Press enter 
• Press start to begin program 11 
Once the program has run through completion and the pressure inside the chamber returns to 
atmospheric pressure, the hood can be opened using the switch on the right side of the machine. 
Next remove the lid using the hand wrench. The centrifuge tubes can then be removed carefully 
and with as little agitation as possible. It is even suggested to extract the aqueous face while the 
tubes are at the centrifuge to stop the agitation created when walking with the samples. Figure 22 
shows the centrifuge apparatus used during this investigation. 
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Figure 22: Centrifuge System 
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A.5. Freeze Drying 
Labcono Freeze Dry System/Freezone® 4.5 
Alcatel rotary pump 
 
 After the emulsions were prepared freeze drying was performed to test the stability of the 
emulsions. Samples of the emulsions (1ml) were placed in 5mL plastic centrifuge tubes. About 
five or six holes were punched into the caps of the centrifuge tubes using a needle to allow air to 
flow out of the tubes during lyophilization. Once all the tubes were sealed using the caps they 
were properly labeled and an elastic band was used to hold all the tubes together.  
Liquid nitrogen was then poured into a Styrofoam container and the tubes were 
immerged in the container and rotated until all the emulsions within the tubes had frozen solid. 
The emulsions were then placed in a big glass container and attached to the Labcono Freeze 
Drying System. A paper towel was then folded and placed under the container for support.  
The pump attached to the freeze drying system was turned on to activate the vacuum 
system. The valve that connected the glass flask and the apparatus was then turned clockwise in 
a very slow motion until the motor pump made a distinct noise indicating that the pressure in the 
system was increasing. The valve was turned until it was parallel with the top of the flask. The 
pump kept going until the pressure stabilized ceasing the noise and starting the drying process. 
The samples were left in the freeze drying system for a period of 48 hours where the sample had 
sufficient time to dry. 
To remove the flask from the drying system the valve connecting the glass flask to the 
apparatus was turned counterclockwise where the pressure starts releasing and the flask was then 
removed from the system. The rotary pump as well as the freeze drying apparatus was then 
switched off.  
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The dried product was reconstituted in the individual tubes by adding 1ml of solvent and 
sonicating the tubes in a sonic bath for 10min. The solutions were then vortexed, and retested for 
particle size. Figure 23 shows the freeze drying apparatus used during this investigation. 
 
 
 
Figure 23: Labcono Freeze Drying System 
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A.6. UV Spectroscopy 
  UV-2101 PC Shimadzu 2nd Floor 
 
After turning on the computer and the UV spec the program was opened and allowed to 
perform a self-check. Upon completion of the check, the parameters were adjusted to meet our 
analytical needs. Specifically, the wavelength was adjusted to 500nm and 190nm and the speed 
to medium. The other settings in default included measuring mode, Abs; Recording Range 0 to 
2.5; Slit Width (nm) 1.0; and Sampling Interval Auto. 
After thoroughly washing and drying the cuvettes before each experiment, a baseline 
reference was run with the solvent solution. Afterwards the samples were prepared and ran in 
turn. Clicking on the start prompted the UV to run the spec, and when it was completed clicking 
on the “Go to WL” with wavelength 262 provided the absorbance of lidocaine. Three readings 
were taken each time to minimize experimental error.  
Figure 24 shows the UV spectrophotometer used during this investigation. 
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Figure 24: UV Spectrophotometer 
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A.7. Dialysis Membrane 
 The Spectra/Por membrane was used for drug release kinetics testing. In order to use the 
membrane one must cut the desired length and place the membrane into a beaker filled with 
MilliQ water to properly wash the membrane. The solution surrounding the membrane was 
tested for purity with the UV, and replaced until there were no longer impurities coming from the 
membrane.  
 Once clean, a desired about of membrane was cut, one end was tied closed, and the 
emulsion solutions were poured into the remaining opening before it was also tied closed. The 
membrane was rinsed off at the ends to remove excess emulsions, and then placed directly in the 
solution bath for release experiments. 
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Appendix B: Data 
B.1. Particle Sizer Data 
Polymer Conc. 
in Aqueous Oil Fraction 
Z-avg 
(nm) 
Mean count 
rate PDI Age (hr) 
Minimum 
(nm) 
Maximum 
(nm) 
  
0.1mg/ml 10% 754.5 286.3 0.728 2 661 813  
0.1mg/ml 10% 1499.3 340.3 0.470 172 1370 1577  
0.75mg/ml 10% 658.1 265.0 0.466 4 654 663  
0.75mg/ml 10% 800.2 230.0 0.329 172 795 804  
1.4mg/ml (1) 10% 492.6 239.3 0.262 4 487 497  
1.4mg/ml (1) 10% 801.1 182.7 0.107 144 796 806  
1.4mg/ml (1) 10% 777.1 211.0 0.382 199 765 789 Centrifuged 
1.4mg/ml (1) 10% 868.8 210.3 0.564 199 825 900 Freeze Dry 
1.4mg/ml (2) 10% 654.0 272.3 0.274 1 631 678  
1.4mg/ml (2) 10% 751.0 239.8 0.113 48 718 768  
1.4mg/ml (2) 10% 835.2 330.0 0.263 104 827 844 Centrifuged 
1.4mg/ml (2) 10% 1026.4 240.3 0.473 103 987 1105 Freeze Dry 
2.0mg/ml 10% 774.2 248.3 0.282 4 767 779  
2.0mg/ml 10% 880.2 259.3 0.108 173 875 884  
1.3mg/ml NaCl 10% 708.6 370.3 0.259 12 702 716  
1.3mg/ml NaCl 10% 641.7 293.3 0.264 34 621 654  
1.3mg/ml NaCl 10% 654.0 452.7 0.227 37 652 656  
1.3mg/ml NaCl 10% 791.5 352.0 0.250 40 784 803  
1.3mg/ml NaCl 10% 763.8 489.7 0.162 39 752 770 Centrifuged 
1.3mg/ml NaCl 10% 886.4 162.7 0.400 40 860 923 Freeze Dry 
1.4mg/ml NaCl 10% 517.1 291.3 0.219 13 507 525  
1.4mg/ml NaCl 10% 578.4 325.0 0.134 37 568 590  
1.4mg/ml NaCl 10% 614.2 275.7 0.114 38 601 621  
1.4mg/ml NaCl 10% 1167.0 128.0 0.321 40 1167 1167  
1.4mg/ml NaCl 10% 783.9 407.7 0.226 39 773 794 Centrifuged 
1.4mg/ml NaCl 10% 1009.7 257.3 0.496 40 998 1017 Freeze Dry 
1.5mg/ml NaCl 10% 551.6 199.7 0.223 13 533 577  
1.5mg/ml NaCl 10% 653.0 252.0 0.232 34 636 668  
1.5mg/ml NaCl 10% 699.0 356.7 0.145 37 688 715  
1.5mg/ml NaCl 10% 766.4 260.0 0.261 39 740 793 Centrifuged 
1.5mg/ml NaCl 10% 910.9 159.0 0.428 40 888 956 Freeze Dry 
1.4mg/ml 20% 1441.0 342.0 0.639 1 1390 1540  
1.4mg/ml 20% 1970.7 391.3 0.330 79 1900 2010  
2.0mg/ml 20% 865.1 259.3 0.366 1 845 876  
2.0mg/ml 20% 1208.7 366.0 0.304 79 1186 1236  
2.5mg/ml 20% 875.9 260.0 0.418 2 849 899  
2.5mg/ml 20% 1092.3 187.3 0.019 78 1083 1110  
1mg/ml 25% 1542.3 195.3 0.589 43 1468 1613  
1mg/ml 25% 1571.3 260.0 0.598 150 1543 1622 Centrifuged 
1mg/ml 25% 2052.0 319.7 1.000 160 1945 2239 Freeze Dry 
2mg/ml 25% 1270.3 390.3 0.521 24 1237 1330  
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2mg/ml 25% 1474.3 329.7 0.471 43 1433 1536  
2mg/ml 25% 1784.7 279.7 0.367 150 1761 1859 Centrifuged 
2mg/ml 25% 968.8 169.0 0.453 160 932 999 Freeze Dry 
3mg/ml 30% 1692.7 438.7 0.475 6 1658 1722  
3mg/ml 30% 2079.7 297.0 0.329 25 2022 2110  
3mg/ml 30% 2014.0 368.7 0.499 150 1914 2069 Centrifuged 
3mg/ml 30% 1563.0 171.7 0.577 160 1485 1695 Freeze Dry 
4mg/ml 30% 1210.0 501.7 0.294 7 1181 1230  
4mg/ml 30% 1604.7 353.0 0.374 26 1591 1617  
4mg/ml 30% 1181.7 323.3 0.495 160 1161 1207 Freeze Dry 
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B.2. Partition Coefficient Data 
 
1 2 3 Notes:
1 dicaprylyl carbonate 262 0.1384 0.1385 0.1383 0.1383 0.0768 0.0050 0.02074 0.00038 0.02035 0.0050 4.071 53 1:1, 10ml tot
2 caprylic/capric triglyceride 262 0.2574 0.2581 0.2575 0.2565 0.1428 0.0050 0.02074 0.00071 0.02002 0.0050 4.005 28 Started with sat. lido
3 octyldodecanol 262 0.0875 0.0874 0.0877 0.0873 0.0485 0.0050 0.02074 0.00024 0.02049 0.0050 4.099 84
4 miglyol 262 0.2243 0.2250 0.2240 0.2239 0.1245 0.0050 0.02074 0.00062 0.02011 0.0050 4.023 32
1 2 3 Notes:
1 dicaprylyl carbonate 262 0.2249 0.2246 0.2242 0.2260 0.1248 0.0063 0.02592 0.00078 0.02514 0.0038 6.704 54 3:5, 10ml tot
2 caprylic/capric triglyceride 262 0.2948 0.2963 0.2932 0.2948 0.1636 0.0063 0.02592 0.00102 0.02490 0.0038 6.640 41 Started with sat. lido
3 octyldodecanol 262 0.1672 0.1674 0.1673 0.1670 0.0928 0.0063 0.02592 0.00058 0.02534 0.0038 6.758 73
4 miglyol 262 0.3272 0.3274 0.3259 0.3282 0.1815 0.0063 0.02592 0.00113 0.02479 0.0038 6.610 36
1 2 3 Notes:
1 dicaprylyl carbonate 262 0.4211 0.4206 0.4216 0.2336 0.0025 0.01037 0.00058 0.00978 0.0015 6.523 28 3:5, 4ml tot
2 caprylic/capric triglyceride 262 0.4752 0.4752 0.2637 0.0025 0.01037 0.00066 0.00971 0.0015 6.473 25 Started with sat. lido
3 octyldodecanol 262 0.3027 0.3026 0.3027 0.3029 0.1680 0.0025 0.01037 0.00042 0.00995 0.0015 6.632 39
4 miglyol 262 0.6040 0.6020 0.6038 0.6061 0.3351 0.0025 0.01037 0.00084 0.00953 0.0015 6.354 19
1.8023  = ε
saturation conc. = 4.1474 g/l
1 2 3 Notes:
1 octyldodecanol 262 0.1654 0.1654 0.1653 0.1654 0.0918 0.0050 0.03008 0.00046 0.02962 0.0050 5.923 65 1:1, 10ml tot
2 octyldodecanol 262 0.1822 0.1818 0.1827 0.1820 0.1009 0.0050 0.03008 0.00050 0.02957 0.0050 5.914 59
3 octyldodecanol 262 0.1634 0.1635 0.1638 0.1630 0.0907 0.0050 0.03008 0.00045 0.02962 0.0050 5.924 65
4 octyldodecanol 262 0.1757 0.1765 0.1754 0.1753 0.0979 0.0050 0.03008 0.00049 0.02959 0.0050 5.917 60 3.2 = standard dev.
initial oil conc. = 6.02 g/l
Started with 6mg/ml 
lido in oil
final mass 
oil (g) vol oil (l)
c oil final    
g/l Kp
c aq final    
g/l vol aq (l)
initial 
mass oil 
final mass 
aq (g)Oil λ    (nm)
Average 
Absorban
Absorbance
final mass 
oil (g) vol oil (l)
c oil final    
g/l Kp
c aq final    
g/l vol aq (l)
initial 
mass aq 
final mass 
aq (g)Oil λ    (nm)
Average 
Absorban
Absorbance
final mass 
oil (g) vol oil (l)
c oil final    
g/l Kp
c aq final    
g/l vol aq (l)
initial 
mass aq 
final mass 
aq (g)Oil λ    (nm)
Average 
Absorban
Absorbance
final mass 
oil (g) vol oil (l)
c oil final    
g/l Kp
c aq final    
g/l vol aq (l)
initial 
mass aq 
final mass 
aq (g)Oil λ    (nm)
Average 
Absorban
Absorbance
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B.2. Release Kinetics Data 
Alginate Stabilized Emulsion with Lidocaine 
 
Time 
(min) 
Absorbance 
(at 262nm) 
Concentration 
(g/L) 
 
Time 
(min) 
Absorbance 
(at 262nm) 
Concentration 
(g/L) 
0 0 0.0000  78 0.1358 0.0753 
15 0.0374 0.0208  78 0.1339 0.0743 
15 0.0402 0.0223  78 0.1366 0.0758 
15 0.0389 0.0216  81 0.1373 0.0762 
30 0.1214 0.0674  81 0.1373 0.0762 
30 0.1188 0.0659  81 0.1375 0.0763 
30 0.1234 0.0685  88 0.1387 0.0770 
40 0.0728 0.0404  88 0.1362 0.0756 
40 0.0727 0.0403  88 0.1396 0.0775 
40 0.0754 0.0418  88 0.1377 0.0764 
45 0.1636 0.0908  104 0.1404 0.0779 
45 0.1634 0.0907  104 0.1429 0.0793 
45 0.1613 0.0895  104 0.1426 0.0791 
48 0.1249 0.0693  104 0.1433 0.0795 
48 0.1249 0.0693  120 0.1468 0.0815 
48 0.1253 0.0695  120 0.1488 0.0826 
51 0.1262 0.0700  120 0.1486 0.0825 
51 0.1258 0.0698  120 0.1471 0.0816 
51 0.1265 0.0702  146 0.1497 0.0831 
57 0.1307 0.0725  146 0.1507 0.0836 
57 0.1312 0.0728  146 0.1506 0.0836 
57 0.1295 0.0719  216 0.1615 0.0896 
60 0.1332 0.0739  216 0.1607 0.0892 
60 0.1339 0.0743  216 0.1619 0.0898 
60 0.1337 0.0742  276 0.1599 0.0887 
63 0.1321 0.0733  276 0.1597 0.0886 
63 0.1329 0.0737  276 0.1636 0.0908 
63 0.1335 0.0741  276 0.1614 0.0896 
63 0.1299 0.0721  366 0.1761 0.0977 
70 0.1361 0.0755  366 0.1787 0.0992 
70 0.1345 0.0746  366 0.1796 0.0997 
70 0.1366 0.0758  366 0.1813 0.1006 
78 0.1359 0.0754     
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Lidocaine and Alginate 
 
Time 
(min) 
Absorbance 
(at 262nm) 
Concentration 
(g/L) 
0 0 0.0000 
15 0.0258 0.0143 
30 0.0498 0.0276 
30 0.0499 0.0277 
45 0.0633 0.0351 
45 0.0627 0.0348 
60 0.0918 0.0509 
60 0.0922 0.0512 
90 0.1492 0.0828 
90 0.1487 0.0825 
120 0.1764 0.0979 
120 0.1776 0.0985 
150 0.1891 0.1049 
150 0.1879 0.1043 
240 0.2255 0.1251 
240 0.2242 0.1244 
285 0.2417 0.1341 
285 0.2387 0.1324 
345 0.247 0.1370 
345 0.2426 0.1346 
405 0.241 0.1337 
405 0.2422 0.1344 
412 0.2414 0.1339 
412 0.243 0.1348 
470 0.2534 0.1406 
470 0.2521 0.1399 
475 0.2486 0.1379 
475 0.249 0.1382 
510 0.2499 0.1387 
510 0.2505 0.1390 
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Appendix C: Calculations 
C.1. Calculation of Volume of 1-Bromo-dodecane to add for certain 
rate of alkyl chain addition 
 
 
V =              0.9 × m × β × 249 × 103         .                 
           1.04 × [∝ × 417 + (100 - ∝ ) × 198] 
 
 
m: mass of AATBA = 15.31 
∝: percentage of acidic functions = 70 
β: rate of chain fixing = 8 
dC12H25Br = 1.04 
MC12H25Br = 249 g/mol 
MAA = 176 g/mol 
MAATBA  = 417g/mol 
MAANa = 198g/mol 
 
Derivation: 
 
Number of moles of AATBA: 
 
(1-0.1) × m   with M = ∝ × 417 + (100 - ∝ ) × 198 
       M                                             100 
 
Number of moles of 1-Bromo-dodecane necessary for given rate of alkyl chain addition: 
 
(1-0.1) m × β   
    M × 100 
 
In volume = (1-0.1) × m × β × 249 × 103          (in µl) 
                       
              M × 100 × 1,04 
 
 
V =              0.9 × m × β × 249 × 103         .                 
           1.04 × [∝ × 417 + (100 - ∝ ) × 198] 
